BioCorRx Inc. (BICX)
- Previous Close
0.7800 - Open
0.7800 - Bid --
- Ask --
- Day's Range
0.7800 - 0.7800 - 52 Week Range
0.6720 - 2.2200 - Volume
2,500 - Avg. Volume
1,083 - Market Cap (intraday)
6.876M - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4500 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program for substance abuse that includes peer recovery support; and distributes UnCraveRx weight loss management program, a medically assisted weight management program. The company is also developing BICX101, an injectable and implantable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
www.biocorrx.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BICX
Performance Overview: BICX
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BICX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BICX
Valuation Measures
Market Cap
6.88M
Enterprise Value
8.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
73.00
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-404.57%
Return on Equity (ttm)
--
Revenue (ttm)
89.16k
Net Income Avi to Common (ttm)
-3.77M
Diluted EPS (ttm)
-0.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
65.22k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-883.08k
Research Analysis: BICX
Company Insights: BICX
BICX does not have Company Insights